LEAST

1. Age 18 years or above on the date of randomization.

2. EVT for an LVO in the anterior circulation, defined as the intracranial segment of the internal carotid artery (ICA) and/or the M1 or proximal M2 segment of the middle cerebral artery (MCA).

3. National Institutes of Health Stroke Scale (NIHSS) ≥ 6 points at the time of randomization.

4. Pre-stroke modified Rankin Scale (mRS) 0 or 1.

5. Ability to randomize within 6 hours from the end of EVT.

6. Capable of giving signed informed consent either independently, or by a legally authorized representative (LAR).

1. Pregnancy or breast-feeding.

2. Renal insufficiency (creatinine clearance < 30mL/min).

3. Cirrhosis or severe hepatic dysfunction, characterized by jaundice, encephalopathy or coagulopathy.

4. History of pancreatitis in the year prior to randomization or evidence of acute pancreatitis on randomization.

5. Active sepsis on randomization.

6. Cancer, regionally advanced or metastatic, or for which treatment had been administered within 6 months from randomization, or hematological cancer that is not in complete remission.

7. Any terminal medical condition with life expectancy of less than 3 months.

8. Personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).

9. Body mass index (BMI) less than 19.

10. Known hypersensitivity to GLP-1 RAs.

11. Active treatment with an GLP-1RA prior to randomization.

12. Refusal or inability to administer subcutaneous (SC) injections by the patient or a caregiver.

13. Close affiliation with the investigational site.